1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals For Human Use; ICH Q11 Development and Manufacture of Drug Substances (chemical entities and biotechnological/biological entities), Geneva, Switzerland, 2012.
2. Popkin ME, Borman PJ, Omer BA, Seibert KD, Srivastava S, Lepore JV, Hobson L, Donaubauer J, Curran T, Ide N, Tymonko S, Looker A. The delivery of flexibility from the application of QbD to API development. J Pharm Innov. 2018;13(4):367.
3. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; ICH QM7 Assessment and control of DNA reactive (mutagenic) Impurities in Pharmaceuticals, Geneva, Switzerland, 2015.
4. Teasdale A, Elder D, Fenner S. Genotoxic impurities, strategies for identification and control (chapter 9 strategies for the evaluation of genotoxic impurity risk). New Jersey: Wiley; 2010. p. 221–48.
5. Teasdale A, Fenner S, Ray A, Ford A, Philips A. A tool for the semiquantitative assessment of potentially genotoxic impurity (PGI) carryover into API using physicochemical parameters and process conditions. Org Process Res Dev. 2010;14:943–5.
https://doi.org/10.1021/op100071n
.